Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Maria Frezza

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Critical Reviews in Oncology/Hematology|May 8, 2026
Management of Atypical Cartilaginous Tumors (ACT) An Italian Sarcoma Group Consensus DocumentDomenico A Campanacci, Giacomo Giulio Baldi, Roberto Scanferla, et al.
Critical Reviews in Oncology/Hematology|June 27, 2026
Corrigendum to "Management of atypical cartilaginous tumors (ACT): An Italian Sarcoma Group (ISG) consensus document" [Crit. Rev. Oncol. Hematol. 223 (2026) 105358]Domenico Andrea Campanacci, Giacomo Giulio Bald, Roberto Scanferla, et al.
Cancer|September 20, 2019
Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma NetworkAnna Maria Frezza, Tarek Assi, Salvatore Lo Vullo, et al.
JAMA Oncology|May 26, 2018
Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case SeriesAnna Maria Frezza, Robin L Jones, Salvatore Lo Vullo, et al.
Cancer Treatment Reviews|August 11, 2025
How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancersSilvia Stacchiotti, Pan Pantziarka, Hugh Leonard, et al.
Plos One|August 12, 2024
The observational EURACAN prospective clinical registry dedicated to epithelioid hemangioendothelioma: The protocol of an international and collaborative effort on an ultra-rare entityAnna Maria Frezza, Hugh Leonard, Ninna Aggerholm-Pedersen, et al.
Cancer Treatment Reviews|April 11, 2024
Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma GroupElena Palassini, Giacomo Giulio Baldi, Sara Sulfaro, et al.
Critical Reviews in Oncology/Hematology|September 25, 2025
Extended molecular profiling in mesenchymal tumors: a consensus paper from the Italian Sarcoma GroupLorenzo D'Ambrosio, Marta Sbaraglia, Alessandra Merlini, et al.
Cancer|April 28, 2021
Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entitiesSilvia Stacchiotti, Anna Maria Frezza, Jean-Yves Blay, et al.
Cancer Treatment Reviews|August 28, 2022
Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatmentsSilvia Stacchiotti, Anna Maria Frezza, George D Demetri, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Critical Reviews in Oncology/Hematology|May 8, 2026
Management of Atypical Cartilaginous Tumors (ACT) An Italian Sarcoma Group Consensus DocumentDomenico A Campanacci, Giacomo Giulio Baldi, Roberto Scanferla, et al.
Critical Reviews in Oncology/Hematology|June 27, 2026
Corrigendum to "Management of atypical cartilaginous tumors (ACT): An Italian Sarcoma Group (ISG) consensus document" [Crit. Rev. Oncol. Hematol. 223 (2026) 105358]Domenico Andrea Campanacci, Giacomo Giulio Bald, Roberto Scanferla, et al.
Cancer|September 20, 2019
Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma NetworkAnna Maria Frezza, Tarek Assi, Salvatore Lo Vullo, et al.
JAMA Oncology|May 26, 2018
Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case SeriesAnna Maria Frezza, Robin L Jones, Salvatore Lo Vullo, et al.
Cancer Treatment Reviews|August 11, 2025
How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancersSilvia Stacchiotti, Pan Pantziarka, Hugh Leonard, et al.
Plos One|August 12, 2024
The observational EURACAN prospective clinical registry dedicated to epithelioid hemangioendothelioma: The protocol of an international and collaborative effort on an ultra-rare entityAnna Maria Frezza, Hugh Leonard, Ninna Aggerholm-Pedersen, et al.
Cancer Treatment Reviews|April 11, 2024
Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma GroupElena Palassini, Giacomo Giulio Baldi, Sara Sulfaro, et al.
Critical Reviews in Oncology/Hematology|September 25, 2025
Extended molecular profiling in mesenchymal tumors: a consensus paper from the Italian Sarcoma GroupLorenzo D'Ambrosio, Marta Sbaraglia, Alessandra Merlini, et al.
Cancer|April 28, 2021
Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entitiesSilvia Stacchiotti, Anna Maria Frezza, Jean-Yves Blay, et al.
Cancer Treatment Reviews|August 28, 2022
Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatmentsSilvia Stacchiotti, Anna Maria Frezza, George D Demetri, et al.
Pageof 7